Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

Targeting of HER2-positive tumors with trastuzumab has shown to improve survival in early stage and advanced breast cancer. The addition of pertuzumab, another anti-HER2 antibody, to trastuzumab-containing regimens has demonstrated a modest increase in disease-free survival in the adjuvant setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Ocaña, Alberto, Amir, Eitan, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112749/
https://www.ncbi.nlm.nih.gov/pubmed/30159132
http://dx.doi.org/10.18632/oncotarget.25739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112749/
https://www.ncbi.nlm.nih.gov/pubmed/30159132
http://dx.doi.org/10.18632/oncotarget.25739

Ejemplares similares